ENLV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Enlivex Ltd (ENLV) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock shows weak technical indicators, no significant trading trends, and mixed financial performance. While there are positive catalysts such as FDA approval for a Phase 2b trial and a share buyback program, the recent financial data and lack of strong proprietary trading signals suggest that holding off on investment is prudent.
The MACD is negatively expanding, RSI is neutral at 47.145, and moving averages are converging, indicating no clear trend. The stock is trading below its pivot level of 1.142, with key support at 1.025 and resistance at 1.259. Overall, the technical indicators suggest a weak price trend.
FDA approval for a Phase 2b trial of Allocetra™ targeting knee osteoarthritis, $20 million share buyback program, and strong net income of $1.23 billion in 2025 driven by treasury asset appreciation.
Significant regular market price drop of -9.17%, weak financial performance in Q3 2025 with net income down -15.26% YoY and EPS down -25.00% YoY, and no significant hedge fund or insider trading activity.
In Q3 2025, revenue remained flat at 0 with no YoY growth, net income dropped to -$2.205 million (-15.26% YoY), and EPS declined to -0.09 (-25.00% YoY). Gross margin also remained flat at 0.
No analyst rating or price target changes available for ENLV.
